LEADER 04101nam 2200637Ia 450 001 9910841344003321 005 20230607214110.0 010 $a1-280-27111-6 010 $a9786610271115 010 $a0-470-66827-X 010 $a0-470-85929-6 010 $a0-470-86079-0 035 $a(CKB)111087027094322 035 $a(EBL)152690 035 $a(SSID)ssj0000206255 035 $a(PQKBManifestationID)11174701 035 $a(PQKBTitleCode)TC0000206255 035 $a(PQKBWorkID)10226918 035 $a(PQKB)10074680 035 $a(MiAaPQ)EBC152690 035 $a(OCoLC)85820041 035 $a(EXLCZ)99111087027094322 100 $a20021223d2002 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aMucus hypersecretion in respiratory disease$b[electronic resource] 210 $aChichester, West Sussex, England ;$aHoboken, NJ, USA $cWiley$d2002 215 $a1 online resource (304 p.) 225 1 $aNovartis Foundation symposium ;$v248 300 $a"Editors, Derek J. Chadwick and Jamie A. Goode"--P. [v]. 300 $a"Symposium on Mucus Hypersecretion in Respiratory Disease, held at the Novartis Foundation, London, 26-28 February 2002"--P. [v]. 311 $a0-470-84478-7 320 $aIncludes bibliographical references and indexes. 327 $aMUCUS HYPERSECRETION IN RESPIRATORY DISEASE; Contents; Participants; Chair's introduction; Epidemiological studies in mucus hypersecretion; Discussion; Post-secretory fate of host defence components in mucus; Discussion; Mechanisms of submucosal gland morphogenesis in the airway; Discussion; Mucin-producing elements and inflammatory cells; Discussion; Respiratory tract mucins: structure and expression patterns; Discussion; Development and validation of a lectin-based assay for the quantitation of rat respiratory mucin; Discussion; Regulation of mucin secretion from in vitro cellular models 327 $aDiscussionOscillations of pH inside the secretory granule control the gain of Ca(2+) release for signal transduction in goblet cells exocytosis; Discussion; A calcium-activated chloride channel blocker inhibits goblet cell metaplasia and mucus overproduction; Discussion; Mechanisms by which Gram-positive bacteria and tobacco smoke stimulate mucin induction through the epidermal growth factor receptor (EGFR); Discussion; Non-allergic models of mucous cell metaplasia and mucus hypersecretion in rat nasal and pulmonary airways; Discussion 327 $aCytokine regulation of mucus production in a model of allergic asthmaDiscussion; The role of apoptotic regulators in metaplastic mucous cells; Discussion; Current and future therapies for airway mucus hypersecretion; Discussion; Clinical evaluation of new therapies for treatment of mucus hypersecretion in respiratory diseases; Discussion; Final general discussion; Index of contributors; Subject index 330 $aA number of chronic respiratory diseases including chronic bronchitis, asthma, cystic fibrosis and bronchiectasis are characterized by mucus hypersecretion. Following damage to the airway epithelium, a repair process of dedifferentiation, regenerative proliferation and redifferentiation takes place that is invariably accompanied by mucus hypersecretion as a key element in the host defence mechanism. In chronic respiratory diseases, however, excessive mucus production leads to a pathological state with increased risk of infection, hospitalization and morbidity. An understanding of the mechanism 410 0$aNovartis Foundation symposium ;$v248. 606 $aMucous membrane 606 $aRespiratory organs$xDiseases 615 0$aMucous membrane. 615 0$aRespiratory organs$xDiseases. 676 $a616.2 701 $aChadwick$b Derek$091632 701 $aGoode$b Jamie$0283336 712 02$aNovartis Foundation. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910841344003321 996 $aMucus hypersecretion in respiratory disease$94142337 997 $aUNINA